Henderson D A
The Johns Hopkins Center for Civilian Biodefense Studies, Baltimore, MD, USA.
Clin Infect Dis. 2002 Jan 1;34(1):79-83. doi: 10.1086/323897. Epub 2001 Nov 19.
After eradication, there is a small but finite risk that smallpox and/or poliomyelitis viruses could accidentally escape from a laboratory or be released intentionally. The reintroduction of either virus into a highly susceptible population could develop into a serious catastrophe. To counter such an occurrence will require the use of vaccine, perhaps in substantial quantities. In the United States, new stocks of smallpox vaccine are being procured and arrangements are being made for a standby production facility. Similar provisions need to be considered for polio. To counter an epidemic of polio will require the use of the oral vaccine, which is presently the World Health Organization-recommended vaccine of choice for countries throughout the developing world. In these countries, its continued use is advised because of its ability to induce intestinal immunity, its ability to spread to other susceptible household members and to protect them, its ease of administration, and its low cost.
根除之后,天花病毒和/或脊髓灰质炎病毒仍存在虽小但有限的风险,可能意外从实验室逸出或被故意释放。这两种病毒中的任何一种重新传入高度易感人群都可能演变成一场严重灾难。应对此类事件将需要使用疫苗,或许数量可观。在美国,正在采购新的天花疫苗库存,并在筹备备用生产设施。对于脊髓灰质炎也需要考虑类似的准备措施。应对脊髓灰质炎疫情将需要使用口服疫苗,目前这是世界卫生组织为整个发展中世界各国推荐的首选疫苗。在这些国家,建议继续使用该疫苗,因为它能够诱导肠道免疫、能够传播给其他易感家庭成员并保护他们、易于接种且成本低廉。